AMC MCQ (CAT) obstetrics & gynaecology questions

At a beta-hCG level above the discriminatory zone (typically 1500-2000 IU/L), an intrauterine pregnancy should usually be visible on transvaginal ultrasound; its absence, with no adnexal mass seen, is classified as a pregnancy of unknown location rather than a confirmed ectopic. Management requires serial beta-hCG measurement 48 hours apart to determine the trend, since a normally rising level suggests an early viable intrauterine pregnancy, a falling level suggests a failing pregnancy, and a plateauing or suboptimally rising level raises concern for ectopic pregnancy. This patient has no bleeding history to support complete miscarriage and no mass to confirm ectopic or heterotopic pregnancy. Free fluid alone is nonspecific and can occur with a ruptured corpus luteum cyst or early ectopic.

• A. A corpus luteum cyst would typically be visualised as an adnexal structure on ultrasound, which was not seen.
• B. Heterotopic pregnancy requires visualisation of both an intrauterine and an ectopic gestation, and no intrauterine sac is seen.
• D. Threatened miscarriage requires visualisation of an intrauterine pregnancy with bleeding, neither of which applies here.
• E. Complete miscarriage requires a history of passing tissue or bleeding with a previously confirmed intrauterine pregnancy, which is absent here.

In a haemodynamically stable woman with a confirmed first-trimester miscarriage, expectant management is a reasonable first-line option and is associated with success rates of around 80% within 2-4 weeks, particularly when the gestational sac is small. All three management options (expectant, medical with misoprostol, and surgical) should be discussed, and patient preference guides the choice when there is no contraindication such as infection, heavy bleeding or haemodynamic instability. Methotrexate is used for ectopic pregnancy, not miscarriage. Surgical evacuation is reserved for women who prefer it, have heavy bleeding, infection, or failed expectant or medical management.

• A. Methotrexate is used to treat ectopic pregnancy by inhibiting trophoblast proliferation, not miscarriage.
• B. Oxytocin is used for labour induction and postpartum haemorrhage, not for first-trimester miscarriage management.
• C. Immediate surgery is not required in a stable patient who prefers to avoid a procedure; it is one option among several, not the mandatory first step.
• D. Emergency curettage is not indicated in a stable patient without heavy bleeding or infection; it is not the first-line choice when expectant management is appropriate.

In Australia, Rh D-negative women who are not already sensitised should receive anti-D immunoglobulin after any sensitising event in pregnancy, including miscarriage, regardless of gestational age or whether management is expectant, medical or surgical. For events in the first trimester, a dose of 250 IU is recommended, given intramuscularly ideally within 72 hours of the event. The 625 IU dose is used for sensitising events from the second trimester onwards (13 weeks and beyond). Partner blood group does not need to be confirmed before giving anti-D, as the priority is preventing maternal sensitisation.

• A. Anti-D is indicated after miscarriage at any gestational age in Rh-negative women to prevent sensitisation.
• C. Anti-D should be given regardless of the method of management of the miscarriage, not only if surgery is performed.
• D. The 625 IU dose is used for sensitising events at or after 13 weeks' gestation, not in the first trimester.
• E. Anti-D should not be withheld while awaiting partner testing; it should be given promptly after a sensitising event.

Methotrexate is appropriate for haemodynamically stable women with an unruptured ectopic pregnancy, a beta-hCG level generally below 5000 IU/L, no fetal cardiac activity, and a small gestational mass without significant free fluid, provided renal and liver function are normal and there are no contraindications. This patient meets all these criteria, making medical management with methotrexate an appropriate alternative to surgery. Surgery is preferred when beta-hCG is very high, fetal cardiac activity is present, there is significant haemoperitoneum, or the patient is unstable. Expectant management is reserved for very low and falling beta-hCG levels, and misoprostol has no role in ectopic pregnancy.

• A. Surgery is not required as first-line when strict medical management criteria are met and the patient prefers to avoid an operation.
• B. Misoprostol has no established role in the management of ectopic pregnancy, as it does not address trophoblastic tissue outside the uterus.
• C. A laparotomy is more invasive than necessary when laparoscopic or medical options are suitable and the patient is stable.
• E. Expectant management is reserved for very low, spontaneously falling beta-hCG levels, not a level of 4800 IU/L with ongoing symptoms.

The RACGP and the Australian Pregnancy Care Guidelines recommend that the first antenatal visit occur as early as possible, ideally before 10 weeks' gestation, to allow timely dating, risk assessment, discussion of screening options, and early identification of medical, social and pregnancy-specific risk factors. This visit should include a comprehensive history, physical examination, and baseline investigations such as full blood count, blood group and antibody screen, infectious disease serology, and urine culture. Aboriginal and Torres Strait Islander women benefit from early, culturally safe antenatal engagement, ideally through models of care involving Aboriginal health workers, rather than delayed or bypassed general practice care. Delaying the first visit to coincide with screening tests or the anatomy scan misses the opportunity for early risk assessment and timely intervention.

• A. Aboriginal and Torres Strait Islander women should still receive early general practice-based antenatal care, ideally with culturally appropriate support, not bypass to obstetric referral alone.
• B. Deferring booking until 12 weeks delays important early risk assessment, dating and baseline investigations that should occur before 10 weeks.
• C. Waiting for quickening is outdated and delays essential early antenatal assessment and investigations.
• E. Waiting until the anatomy scan at 18-20 weeks is far too late for essential early pregnancy care and screening discussions.

For women at average risk without risk factors for neural tube defects, the recommended preconception and early pregnancy dose of folic acid is 500 micrograms daily, commenced at least one month before conception and continued through the first trimester to reduce the risk of neural tube defects. Iodine supplementation of 150 micrograms daily is also recommended for all women who are planning pregnancy, pregnant, or breastfeeding, to support fetal neurodevelopment, and should ideally begin before conception as well. The higher 5 mg dose of folic acid is reserved for women at increased risk, such as those with a personal or family history of neural tube defects, diabetes, or on certain antiepileptic medications. Waiting until pregnancy is confirmed or until a missed period misses the critical early window of neural tube closure, which occurs very early in gestation.

• A. This dose of folic acid is appropriate only for high-risk women, and the iodine dose of 500 micrograms exceeds the standard recommended preconception dose of 150 micrograms.
• B. Iodine supplementation at 150 micrograms daily is recommended for all women planning pregnancy, not omitted.
• C. The 5 mg dose is reserved for women at increased risk of neural tube defects, and supplementation should start before conception rather than after pregnancy is confirmed.
• E. Supplementation should begin at least one month before conception, not delayed until after a missed period, since neural tube closure occurs very early in gestation.

A 1 in 50 risk on combined screening is high-risk and warrants further investigation, but NIPT is an appropriate intermediate step for a woman who wants to avoid the procedural miscarriage risk of invasive testing. NIPT has very high sensitivity and specificity for trisomy 21 but remains a screening test; a positive result must be confirmed with chorionic villus sampling or amniocentesis before any irreversible decision is made, and counselling must make this clear. Invasive testing can be reserved for those with a positive NIPT result or for women who prefer diagnostic certainty immediately.

• A. A 1 in 50 risk is high-risk and should not be reassured away without further testing.
• C. Repeating the same screening test does not change the fundamental risk and delays appropriate follow-up.
• D. Chorionic villus sampling is invasive and carries a procedural miscarriage risk; it is not the first step when a non-invasive option is appropriate and desired.
• E. Amniocentesis is invasive and skips the non-invasive option this patient has specifically requested; it also should not proceed without counselling.

Australian guidelines (ADIPS, aligned with IADPSG criteria) recommend a 75 g oral glucose tolerance test between 24 and 28 weeks gestation for women without early risk factors. Gestational diabetes is diagnosed if any one of the following is met: fasting plasma glucose 5.1 mmol/L or higher, 1-hour glucose 10.0 mmol/L or higher, or 2-hour glucose 8.5 mmol/L or higher. These thresholds are lower than those used for overt diabetes because even mild hyperglycaemia in pregnancy increases risk of macrosomia and adverse perinatal outcomes. Women with high-risk factors (previous GDM, obesity, strong family history) are screened earlier, around 10-14 weeks, with the same test and thresholds.

• A. A fasting threshold of 4.0 mmol/L is far too low and would misclassify most normal pregnancies as diabetic; the correct fasting threshold is 5.1 mmol/L.
• B. The 50 g 1-hour challenge test is an older screening approach not used in current Australian guidelines, which favour the 75 g diagnostic OGTT.
• C. HbA1c is not recommended for diagnosing gestational diabetes because it reflects glycaemia over the preceding 2-3 months and lacks sensitivity in pregnancy.
• E. A single random glucose is not a validated diagnostic test for gestational diabetes.

When diet and lifestyle measures fail to achieve glycaemic targets (fasting <5.3 mmol/L, 2-hour postprandial <6.7 mmol/L) in gestational diabetes, pharmacological therapy is indicated. Metformin is commonly used as first-line oral therapy in Australian practice due to its favourable safety profile and ease of use, with insulin added or substituted if targets remain unmet. Insulin remains the most effective agent and is preferred when rapid or tight control is needed, but metformin is a reasonable and guideline-supported initial step for persistent mild hyperglycaemia. Bed rest and further carbohydrate restriction do not address the underlying insulin resistance and risk fetal undernutrition, and induction is not indicated based on glucose readings alone without other obstetric indications.

• A. Bed rest does not improve insulin sensitivity and increases risk of venous thromboembolism without glycaemic benefit.
• C. Further dietary restriction has already been trialled and is unlikely to achieve targets; delaying treatment risks fetal macrosomia.
• D. Induction is not indicated purely for glucose levels above target without other fetal or maternal indications at this gestation.
• E. Sulfonylureas such as glibenclamide are not first-line in pregnancy due to a less favourable safety and efficacy profile compared with metformin and insulin.

Microcytic, hypochromic anaemia in a woman from a population with a high prevalence of haemoglobinopathies (Mediterranean, Southeast Asian, Middle Eastern, African) should prompt both iron studies and a haemoglobinopathy screen, since iron deficiency and thalassaemia trait can coexist or mimic each other. Identifying a haemoglobinopathy in the mother allows partner testing and, if both parents carry a clinically significant trait, genetic counselling and consideration of prenatal diagnosis for conditions such as beta-thalassaemia major. Treating empirically with iron without first excluding thalassaemia trait risks missing an important genetic diagnosis with reproductive implications.

• A. Bone marrow biopsy is invasive and not indicated for microcytic anaemia in pregnancy without features suggesting marrow failure.
• B. Empirical iron treatment without haemoglobinopathy screening may mask or delay diagnosis of thalassaemia trait, which has implications for the fetus.
• C. Delaying investigation misses an opportunity for early genetic counselling if a haemoglobinopathy is present.
• E. Reticulocyte count alone does not distinguish iron deficiency from haemoglobinopathy and is insufficient as the next step.

Australian practice recommends a combined low vaginal and rectal swab for Group B Streptococcus culture at 35-37 weeks gestation. If positive, intrapartum intravenous benzylpenicillin (or ampicillin) is given from the onset of labour or rupture of membranes until delivery to reduce vertical transmission and neonatal early-onset sepsis. Antenatal oral antibiotic treatment of colonisation is not effective because it does not eliminate recolonisation before labour; prophylaxis must be given intrapartum. Screening too early in pregnancy, such as at 20 weeks, does not reliably predict colonisation status at the time of birth.

• A. Urine culture detects significant bacteriuria but is not the recommended screening method for GBS colonisation.
• B. Oral antenatal treatment does not reliably clear colonisation before labour and intravenous intrapartum prophylaxis is required instead.
• C. Screening at 20 weeks is too early and does not predict colonisation at the time of delivery; oral treatment does not prevent recolonisation.
• E. Universal intrapartum antibiotics without screening is not standard practice; a risk-based or screening-based approach is used.

In Australia, Rhesus D negative women with a negative antibody screen are offered routine antenatal anti-D immunoglobulin prophylaxis at 28 and 34 weeks gestation, regardless of partner blood group, because partner testing is not always reliable or available and the risk of sensitisation from silent fetomaternal haemorrhage increases as pregnancy progresses. Additional doses are given after any potentially sensitising event, such as bleeding, abdominal trauma or invasive procedures. Postnatal anti-D is also given if the baby is confirmed Rhesus D positive. This two-dose antenatal schedule reduces the risk of alloimmunisation that could complicate this or future pregnancies.

• A. Monthly dosing is not the standard schedule and is unnecessarily frequent; the standard regimen is two doses in the third trimester.
• B. Prophylaxis should not be withheld based on uncertain partner blood group, since fetal blood group cannot otherwise be reliably assumed.
• D. A single dose at 28 weeks only is insufficient; current guidelines recommend two routine antenatal doses, at 28 and 34 weeks.
• E. Waiting until after delivery misses the antenatal prophylaxis window and does not prevent sensitisation that can occur earlier in pregnancy.

Culturally safe antenatal care for Aboriginal and Torres Strait Islander women is best delivered through continuity of carer models that integrate Aboriginal Health Workers or Aboriginal Health Liaison Officers, ideally coordinated with Aboriginal Community Controlled Health Services. This approach builds trust, improves attendance and engagement, and has been shown to improve outcomes such as earlier initiation of antenatal care and reduced preterm birth compared with standard mainstream care alone. Given this woman's previous difficult experience and distrust of mainstream services, a known, culturally safe caregiver model addresses these barriers directly. Purely remote, self-directed, or unsupported mainstream referral pathways do not address the relational and cultural barriers to engagement described.

• A. A distant private obstetrician does not address access barriers or cultural safety concerns and reduces continuity.
• B. Self-directed care with written information alone is insufficient given her risk factors and history of limited antenatal engagement.
• C. Telehealth-only care without face-to-face contact is inadequate for necessary clinical examinations and monitoring in pregnancy.
• D. Standard mainstream referral without cultural support does not address her stated distrust and risks disengagement from care.

The Australian Immunisation Handbook recommends dTpa (pertussis-containing) vaccine be given in each pregnancy, ideally between 20 and 32 weeks gestation, to maximise passive antibody transfer to the neonate before the primary vaccination series begins, reducing the risk of severe pertussis in early infancy. Influenza vaccine is recommended for all pregnant women at any stage of pregnancy, as pregnant women are at increased risk of complications from influenza infection. Both vaccines are inactivated and safe throughout pregnancy. Vaccination should occur in every pregnancy, not just the first, because antibody levels decline over time.

• A. Pertussis vaccination is recommended in every pregnancy regardless of previous vaccination status, and influenza vaccine is not restricted to the first trimester.
• C. Pertussis vaccine is recommended in the 20-32 week window, not only after 36 weeks, and influenza vaccine is safe and recommended at any stage of pregnancy, not deferred.
• D. Pertussis vaccine timing is optimised for the 20-32 week window rather than the first visit, and influenza vaccine should not be withheld.
• E. Both vaccines are inactivated, not live, and are recommended during pregnancy, not contraindicated.

Gestational hypertension is defined as new-onset hypertension (systolic ≥140 mmHg or diastolic ≥90 mmHg) arising after 20 weeks gestation, without proteinuria or other features of maternal organ dysfunction. This woman has elevated blood pressure confirmed on repeat measurement but normal protein:creatinine ratio, normal bloods and no symptoms suggestive of end-organ involvement, which excludes pre-eclampsia. Pre-eclampsia requires hypertension plus evidence of maternal organ dysfunction such as proteinuria, renal impairment, liver involvement, neurological features, haematological abnormalities or fetal growth restriction. She requires ongoing surveillance, as gestational hypertension can progress to pre-eclampsia.

• A. There is no history of pre-existing chronic hypertension, so superimposed pre-eclampsia cannot be diagnosed.
• C. Chronic hypertension refers to hypertension predating pregnancy or diagnosed before 20 weeks, not applicable to this new finding at 34 weeks.
• D. Pre-eclampsia requires evidence of maternal organ dysfunction such as significant proteinuria, which is absent here.
• E. White coat hypertension is diagnosed by ambulatory or home monitoring showing normal readings outside the clinic, which has not been assessed here.

Severe hypertension in pregnancy (systolic ≥170 mmHg or diastolic ≥110 mmHg) is a medical emergency requiring urgent treatment to prevent cerebrovascular complications. Therapeutic Guidelines recommend intravenous hydralazine or labetalol as first-line agents for acute severe hypertension in pregnancy, given as a bolus with close monitoring of maternal blood pressure and fetal heart rate. Oral agents have a slower onset and are not appropriate for this hypertensive emergency. The goal is a gradual, controlled reduction in blood pressure to avoid compromising placental perfusion.

• B. ACE inhibitors such as enalapril are contraindicated in pregnancy due to fetotoxicity, including renal failure and oligohydramnios.
• C. Frusemide is a diuretic not indicated for acute severe hypertension and may worsen placental perfusion by reducing intravascular volume.
• D. Spironolactone has anti-androgenic effects in the fetus and is not used for acute blood pressure control in pregnancy.
• E. Atenolol is associated with fetal growth restriction and has a slow onset of action, making it unsuitable for acute severe hypertension.

This woman has clinical features of magnesium toxicity: respiratory depression (rate below 12/min), absent deep tendon reflexes and oliguria, which together indicate an elevated serum magnesium level requiring urgent reversal. The infusion must be stopped immediately and intravenous calcium gluconate given as the specific antidote, as calcium competitively antagonises magnesium at the neuromuscular junction. Magnesium toxicity occurs because magnesium is renally excreted, and reduced urine output allows accumulation to toxic levels; loss of reflexes typically precedes respiratory arrest, making this a critical warning sign. Continuous monitoring of respiratory rate, reflexes and urine output is required throughout magnesium therapy.

• A. Continuing the infusion risks progression to respiratory arrest and cardiac toxicity; this requires immediate intervention, not delayed reassessment.
• C. Naloxone reverses opioid toxicity and has no effect on magnesium-induced neuromuscular blockade.
• D. These findings indicate toxicity, not inadequate prophylaxis, and further magnesium would worsen the clinically dangerous situation.
• E. Reducing the rate alone does not address established toxicity with respiratory depression and absent reflexes; the infusion must be stopped and the antidote given.

This woman has a high-risk factor for pre-eclampsia, a history of pre-eclampsia in a previous pregnancy, which meets criteria for low-dose aspirin prophylaxis (typically 100-150 mg daily) per Therapeutic Guidelines and RACGP recommendations. Aspirin should be commenced ideally before 16 weeks gestation, as its benefit in reducing pre-eclampsia risk is greatest when started early, through its effect on trophoblast invasion and placentation before the window of placental development closes. Starting after 16 weeks substantially reduces the preventive benefit. Aspirin is continued until around 36-37 weeks gestation or delivery.

• A. Starting aspirin after 28 weeks is too late, as the protective effect depends on early initiation before 16 weeks during placental development.
• B. Low-molecular-weight heparin is not indicated for pre-eclampsia prevention in the absence of thrombophilia or recurrent pregnancy loss.
• C. A prior history of pre-eclampsia is a recognised high-risk factor warranting aspirin prophylaxis regardless of current normal blood pressure.
• E. Calcium channel blockers are used for treatment of established hypertension, not for primary prevention of pre-eclampsia.

HELLP syndrome is a severe variant of pre-eclampsia characterised by Haemolysis (schistocytes on film, elevated lactate dehydrogenase, low haemoglobin), Elevated Liver enzymes (raised alanine aminotransferase) and Low Platelets (thrombocytopenia), occurring in the context of hypertension in pregnancy. This woman's combination of hypertension, epigastric pain, microangiopathic haemolysis, transaminitis and thrombocytopenia fits this pattern precisely. HELLP syndrome requires urgent recognition as it is associated with significant maternal morbidity, including hepatic rupture and placental abruption, and typically necessitates expedited delivery. Management involves stabilisation, magnesium sulfate if severe features are present, and timely delivery regardless of gestation once the diagnosis is confirmed.

• A. Thrombotic thrombocytopenic purpura classically occurs outside the context of hypertension and pregnancy-specific liver enzyme elevation, though it can mimic HELLP.
• C. Viral hepatitis would not explain the thrombocytopenia, haemolysis and hypertension seen in this presentation.
• D. Acute fatty liver of pregnancy typically presents with hypoglycaemia, coagulopathy and markedly deranged liver synthetic function, and is not usually associated with hypertension as the primary feature.
• E. Placental abruption causing disseminated intravascular coagulation would typically present with vaginal bleeding and uterine tenderness, not isolated epigastric pain with this biochemical pattern.

This presentation of pruritus affecting palms and soles with raised transaminases and elevated total bile acids in the absence of a skin rash is consistent with intrahepatic cholestasis of pregnancy. The key fetal risk is stillbirth, with risk increasing as bile acid levels rise, particularly above 40 micromol/L and more markedly above 100 micromol/L. Management includes symptomatic treatment, liver function monitoring, and consideration of earlier birth, typically around 36-39 weeks depending on bile acid severity, to reduce stillbirth risk. Ursodeoxycholic acid may be used for symptomatic relief, though its effect on stillbirth risk is less certain.

• A. Obstetric cholestasis is associated with a genuine increase in stillbirth risk, so expectant management to spontaneous term labour without surveillance is not appropriate.
• C. Macrosomia is not a recognised complication of obstetric cholestasis; the primary concern is stillbirth risk, not fetal growth.
• D. Cholestasis of pregnancy is not associated with structural fetal malformation; routine anomaly screening earlier in pregnancy is unaffected by this diagnosis.
• E. The principal risk from obstetric cholestasis is to the fetus, not an increased risk of maternal postpartum haemorrhage.

Cefalexin is a first-line, safe oral antibiotic for lower urinary tract infection in pregnancy at this gestation per Therapeutic Guidelines, with a well-established safety profile and no significant teratogenic or fetal risk across all trimesters. Trimethoprim is a folate antagonist and should be avoided in the first trimester due to neural tube defect risk, though it is an alternative in later pregnancy. Fluoroquinolones such as ciprofloxacin are avoided due to concerns about fetal cartilage and musculoskeletal effects. Tetracyclines such as doxycycline are contraindicated due to effects on fetal teeth and bone. Nitrofurantoin is generally avoided near term due to a theoretical risk of neonatal haemolysis but is more commonly used earlier in pregnancy; cefalexin remains a reliably safe first-line choice throughout pregnancy.

• A. Doxycycline is contraindicated in pregnancy due to effects on fetal tooth discolouration and bone growth.
• B. Trimethoprim is a folate antagonist best avoided, particularly in the first trimester, due to the risk of neural tube defects.
• D. Nitrofurantoin carries a theoretical risk of neonatal haemolysis, particularly if used close to term, making it a less universally preferred option than cefalexin.
• E. Ciprofloxacin is avoided in pregnancy due to potential effects on fetal cartilage and musculoskeletal development.

Painless, bright red vaginal bleeding with a soft, non-tender uterus and a high or unengaged fetal presenting part is classic for placenta praevia, where the placenta overlies or encroaches on the cervical os. Placental abruption typically presents with painful bleeding, uterine tenderness or hypertonus, and often dark blood with signs of fetal compromise. The reassuring fetal heart rate pattern and absence of uterine tenderness further support a praevia rather than abruption. Definitive diagnosis requires ultrasound to localise the placenta before any digital vaginal examination is performed.

• A. Vasa praevia typically presents with painless bleeding accompanying rupture of membranes and acute fetal distress, not spontaneous antepartum bleeding with a reassuring trace.
• B. Abruption usually causes painful bleeding with uterine tenderness or hypertonus, neither of which is present here.
• C. Uterine rupture presents with severe abdominal pain, scar tenderness (usually in a woman with a prior caesarean), and fetal distress, not a soft non-tender uterus.
• E. Cervical ectropion causes light spotting, often postcoital, not a sudden 200 mL bleed at 34 weeks.

In any woman presenting with antepartum haemorrhage and unknown placental location, digital vaginal examination must be avoided until placenta praevia has been excluded, because it can provoke severe haemorrhage by disrupting a low-lying placenta. A transvaginal ultrasound, performed carefully, is safe and accurate for localising the placenta and should be arranged before any digital or speculum examination. Once praevia is excluded, a speculum or digital examination can be performed if clinically indicated. Management should always follow the sequence of resuscitation if required, then imaging, then examination.

• A. Speculum examination carries similar risk to digital examination if a low-lying placenta is present and should not precede ultrasound localisation.
• B. Vaginal packing is not an appropriate initial step and does not address the need to determine placental location.
• C. Oxytocin is not indicated before the cause of bleeding and placental location are established, and could worsen haemorrhage if praevia is present.
• E. Digital vaginal examination is contraindicated until placenta praevia is excluded, as it may precipitate major haemorrhage.

This woman is in preterm labour at 29 weeks gestation with a high likelihood of delivery within 7 days, meeting criteria for antenatal corticosteroids to reduce neonatal respiratory distress syndrome, intraventricular haemorrhage, and neonatal mortality. The standard regimen is intramuscular betamethasone 11.4 mg, two doses 24 hours apart, or alternatively dexamethasone 6 mg intramuscularly in four doses 12 hours apart. Oral or intravenous corticosteroid formulations are not used for fetal lung maturation because they do not achieve the required fetal tissue levels. A single dose is insufficient; the full course maximises benefit, though treatment should not be withheld if delivery is imminent before completion.

• A. Hydrocortisone is not used for antenatal fetal lung maturation; it lacks the required pharmacokinetic profile for this indication.
• C. A single dose of betamethasone is incomplete; the standard course requires two doses 24 hours apart for full benefit.
• D. Dexamethasone for fetal maturation is given intramuscularly in multiple doses, not as a single oral dose.
• E. Oral prednisolone is not an evidence-based route or agent for antenatal corticosteroid therapy for fetal lung maturation.

A symphysis-fundal height more than the expected range below gestational age raises concern for fetal growth restriction and warrants formal ultrasound assessment. This should include fetal biometry to estimate fetal weight, amniotic fluid volume assessment, and umbilical artery Doppler studies, which assess placental function and help guide the timing and intensity of further monitoring. Cardiotocography may be used as an adjunct but does not assess growth or placental perfusion on its own. Waiting two weeks to repeat clinical measurement risks delaying diagnosis of a potentially significant growth problem.

• A. Cardiotocography assesses fetal heart rate patterns but does not evaluate growth, fluid volume, or placental blood flow.
• B. Maternal serum alpha-fetoprotein is used in aneuploidy and neural tube defect screening, not in the assessment of suspected growth restriction.
• C. Amniocentesis for karyotyping is invasive and only indicated if structural anomalies or other markers suggest an underlying chromosomal abnormality, not as a routine investigation for a lagging fundal height.
• D. Delaying reassessment risks missing significant or worsening growth restriction that requires timely monitoring and intervention.

Reduced fetal movements at or after 28 weeks gestation require prompt assessment because they can indicate fetal compromise, including placental insufficiency. The initial assessment should include cardiotocography to evaluate fetal heart rate patterns and a clinical assessment of fetal size, with ultrasound considered if the cardiotocograph is abnormal, if there is a suspicion of growth restriction, or if the mother has ongoing concerns despite a normal trace. A single episode of reduced movements should never be dismissed without formal assessment, as this is a recognised warning sign of stillbirth risk. Reassurance without objective fetal assessment is not appropriate given the clinical significance of this symptom.

• A. Reduced fetal movements require same-day assessment, not deferral to a routine future visit.
• B. Caesarean section is not indicated without evidence of acute fetal compromise from cardiotocography or other assessment.
• C. Delaying assessment for a week to perform fetal movement counting is inappropriate when the mother has already reported a significant reduction requiring prompt evaluation.
• D. Human chorionic gonadotrophin levels are not used to assess fetal wellbeing in the third trimester.

External cephalic version (ECV) is recommended for women with an uncomplicated singleton breech pregnancy at or after 36-37 weeks' gestation, as it reduces the chance of breech presentation at birth and the need for caesarean section. Success rates are around 50%, and contraindications include placenta praevia, ruptured membranes, uterine scarring, or fetal compromise, none of which are present here. ECV should be performed in a setting where facilities for emergency caesarean section are available. Moving straight to elective caesarean or induction with the fetus still breech bypasses a safe, effective option that may allow normal vaginal birth.

• B. Positional techniques have not been shown to reliably convert breech presentation and are not recommended over ECV
• C. Internal podalic version is an obsolete, high-risk technique not used in modern obstetric practice
• D. Induction should not proceed while the fetus remains breech; presentation should be addressed first
• E. Elective caesarean is reasonable if version fails or is declined, but is not the first step when ECV is appropriate and has not been tried

Monochorionic diamniotic twin pregnancies carry a significant risk of twin-twin transfusion syndrome (TTTS), which typically develops between 16 and 24 weeks' gestation due to unbalanced blood flow through placental vascular anastomoses. Fortnightly ultrasound surveillance from 16 weeks, assessing deepest vertical pool of amniotic fluid and bladder filling in each twin, allows early detection of oligohydramnios-polyhydramnios sequence before fetal compromise occurs. Early diagnosis allows timely referral to a fetal medicine unit for consideration of laser ablation of anastomotic vessels. Less frequent surveillance or reliance on CTG would miss the early fluid-volume changes that define TTTS.

• A. Waiting for clinical signs of polyhydramnios means TTTS would already be advanced before investigation; surveillance should be proactive, not symptom-triggered
• B. A single scan at 28 weeks is far too infrequent and too late to detect TTTS, which usually presents earlier
• D. Monthly scans starting at 20 weeks and only assessing growth would miss early TTTS, which is defined by fluid discordance, not growth discordance
• E. CTG does not detect early TTTS, which is identified by amniotic fluid volume discordance on ultrasound, not fetal heart rate changes

Late decelerations with preserved baseline variability suggest uteroplacental insufficiency that is not yet severe, often related to aortocaval compression or excessive uterine activity. The first-line response is conservative: reposition the mother (left lateral position improves uteroplacental perfusion), ensure adequate hydration, correct any hypotension, and consider reducing or stopping oxytocin if running, then reassess the trace. If decelerations persist or variability is lost despite conservative measures, escalation to fetal blood sampling or expedited delivery is indicated. Immediate caesarean section is not warranted when variability is still moderate, as this is a reassuring feature.

• B. There are no signs of infection (afebrile, normal observations); antibiotics are not indicated based on this trace
• C. Oxytocin would worsen uterine activity and uteroplacental insufficiency, aggravating the late decelerations
• D. Routine monitoring without intervention ignores a non-reassuring pattern that requires active conservative management first
• E. Immediate caesarean section is premature when moderate variability is preserved and conservative measures have not yet been tried

Failure to progress in the first stage of labour is defined as less than 2 cm of cervical dilatation over 4 hours despite adequate uterine activity, or inadequate contractions. In a nullipara with intact membranes and inadequate contraction frequency/strength, the appropriate management is to augment labour: artificial rupture of membranes to assess liquor and allow better application of the head, combined with an oxytocin infusion to achieve adequate contractions (aiming for 4-5 in 10 minutes). Caesarean section is reserved for failure to progress despite adequate augmentation, or when there is evidence of obstruction or fetal compromise. The fetal head is not yet engaged low enough, and the cervix is not fully dilated, so instrumental delivery is not an option at this stage.

• A. Analgesia alone does not address the inadequate contraction pattern causing failure to progress
• C. Simply increasing fluids without addressing inadequate uterine activity will not correct the underlying problem of poor contractions
• D. Caesarean section is premature; augmentation with amniotomy and oxytocin should be tried first since contractions are inadequate and there is no evidence of obstruction
• E. Instrumental delivery requires full cervical dilatation; this woman is only 5 cm dilated

The clinical picture, head retraction against the perineum (the 'turtle sign') with failure of shoulders to deliver after gentle traction, is diagnostic of shoulder dystocia due to impaction of the anterior shoulder behind the symphysis pubis. The first-line manoeuvre is the McRoberts position, which flattens the lumbosacral angle and rotates the pubic symphysis superiorly, often resolving the dystocia without further intervention. This should be combined with calling for senior help and avoiding fundal pressure, which increases the risk of further impaction and brachial plexus injury. Caesarean section is not possible once the head has delivered.

• A. Continued traction risks brachial plexus injury and will not resolve true shoulder dystocia
• B. Episiotomy may be used to create space for internal manoeuvres but does not itself relieve bony impaction; McRoberts should be tried first
• C. Caesarean section cannot be performed once the fetal head has already been delivered vaginally
• E. Fundal pressure is contraindicated in shoulder dystocia as it can worsen impaction and increase the risk of fetal injury

Instrumental delivery is indicated in the second stage of labour for fetal compromise or prolonged second stage, provided the cervix is fully dilated, the head is engaged (station +2 or below), position is known, and there is no cephalopelvic disproportion. Here the head is low, direct occiput anterior, and fully dilated, meeting criteria for a safe operative vaginal delivery, and the non-reassuring trace with bradycardia necessitates expedited birth rather than further delay. Caesarean section would be favoured if the head were high, malpositioned, or if operative vaginal delivery were otherwise contraindicated, but it carries greater delay and maternal morbidity when a safe instrumental option exists.

• A. Continued expectant management delays delivery in the setting of a non-reassuring fetal heart trace and is inappropriate
• C. Oxytocin augmentation does not address the urgent need for expedited delivery given fetal compromise and takes too long to be effective
• D. Caesarean section is not the most appropriate option when conditions are favourable for a safe, quicker operative vaginal delivery
• E. Manual rotation is unnecessary as the fetus is already direct occiput anterior; this does not address the need for urgent delivery

A prolonged, unresolving fetal bradycardia with continuous abdominal pain and bleeding is highly suggestive of placental abruption with acute fetal compromise, representing an immediate threat to fetal life. This meets the definition of category 1 caesarean section, which requires delivery as soon as possible, generally within 30 minutes of decision, because there is an immediate threat to the life of the woman or fetus. Category 2 is reserved for compromise that is not immediately life-threatening, allowing somewhat more time, while categories 3 and 4 apply to situations with no acute compromise, where timing is based on logistic or scheduling considerations rather than urgency.

• A. Category 4 is for elective, non-urgent caesarean sections, which is clearly inappropriate in this acute emergency
• B. Category 3 is for cases without maternal or fetal compromise, which does not apply here given the bradycardia and suspected abruption
• C. Category 2 underestimates the urgency; the prolonged unresolving bradycardia with signs of abruption represents an immediate life threat, not a non-immediately-life-threatening compromise
• E. This is not an elective or scheduled procedure; it is an acute emergency requiring immediate delivery

In primary postpartum haemorrhage due to uterine atony, the stepwise approach after initial uterotonics escalates through mechanical and pharmacological measures before surgical intervention. Bimanual uterine massage and compression is a first-line physical measure that stimulates uterine contraction and should be performed promptly alongside additional uterotonics such as ergometrine or carboprost if oxytocin alone is insufficient. Balloon tamponade, B-Lynch sutures, embolisation and hysterectomy are reserved for cases where simpler measures and additional pharmacological agents fail to control bleeding. Hysterectomy is a last resort when conservative and surgical fertility-sparing measures have failed.

• A. Hysterectomy is a last resort reserved for life-threatening haemorrhage unresponsive to all other measures.
• B. Balloon tamponade is used after simpler measures such as massage and additional uterotonics have failed.
• C. Embolisation requires interventional radiology access and is used after simpler first-line measures fail.
• E. A B-Lynch suture is a surgical measure used later in the escalation pathway, not before basic manoeuvres and medical therapy.

Secondary postpartum haemorrhage, defined as abnormal bleeding from 24 hours to 12 weeks postpartum, is most commonly caused by retained products of conception, often complicated by endometritis as in this case with fever, uterine tenderness, and foul discharge. The ultrasound finding of a heterogeneous vascular intrauterine mass supports retained tissue rather than a normally involuted uterus. Uterine atony is a cause of primary, not secondary, PPH and would not explain a focal ultrasound mass at 12 days. Uterine rupture presents acutely with severe pain and haemodynamic compromise, typically in labour or shortly after, not as a subacute presentation at day 12. Cervical ectropion causes light spotting without fever or a uterine mass, and coagulopathy would not produce a focal endometrial mass on ultrasound.

• A. Cervical ectropion causes light spotting, not heavy bleeding with fever, uterine tenderness and an intrauterine mass.
• B. Uterine atony is a cause of primary PPH occurring within the first 24 hours, not secondary PPH at day 12.
• C. Uterine rupture presents with acute severe pain and shock, typically during or immediately after labour, not as a subacute illness.
• D. Coagulopathy would cause diffuse bleeding without a focal vascular intrauterine mass on ultrasound.

Postpartum endometritis is a clinical diagnosis based on fever, uterine tenderness, and malodorous lochia, typically occurring within the first few days after delivery, with risk factors including caesarean section and prolonged rupture of membranes. The combination of fundal tenderness and foul-smelling lochia in a febrile postpartum woman after caesarean section with prolonged membrane rupture strongly supports this diagnosis. Wound infection is excluded by the clean, non-erythematous wound appearance. Urinary tract infection is excluded by the unremarkable urinalysis, and mastitis would present with breast findings, not uterine tenderness. Pelvic deep vein thrombosis typically causes unilateral leg or pelvic pain rather than the described findings of fundal tenderness with foul lochia.

• A. Mastitis presents with localised breast tenderness, erythema or a palpable lump, not uterine tenderness and foul lochia.
• C. Urinalysis is unremarkable, making urinary tract infection unlikely as the cause of her fever.
• D. The wound is clean with no erythema or discharge, making wound infection unlikely.
• E. Pelvic deep vein thrombosis typically presents with unilateral leg swelling or pain, not fundal tenderness and malodorous discharge.

Flucloxacillin is the first-line oral antibiotic for lactational mastitis according to Therapeutic Guidelines, as it provides effective cover against Staphylococcus aureus, the most common causative organism, and is considered safe to continue during breastfeeding. Continued breastfeeding or expressing from the affected breast should be encouraged alongside antibiotics to promote drainage. Cephalexin is a reasonable alternative in penicillin allergy but is not first-line when there is no allergy. Clindamycin is reserved for penicillin-allergic women or suspected methicillin-resistant Staphylococcus aureus. Trimethoprim-sulfamethoxazole and doxycycline are not recommended during breastfeeding due to risks to the infant, including kernicterus and dental staining respectively.

• A. Trimethoprim-sulfamethoxazole carries a risk of kernicterus in the breastfed infant and is avoided in lactation.
• B. Doxycycline can cause dental staining in the infant and is avoided during breastfeeding.
• C. Cephalexin is a second-line alternative used mainly for penicillin allergy, not the first choice here.
• D. Clindamycin is reserved for penicillin allergy or suspected resistant staphylococcal infection.

The Edinburgh Postnatal Depression Scale (EPDS) is the validated screening tool recommended by Australian perinatal mental health guidelines and the RACGP for use in the postnatal period, with a score of 13 or more indicating a high likelihood of depression requiring further clinical assessment. It is a 10-item self-report questionnaire specifically designed and validated for the perinatal population, unlike generic depression or anxiety scales. The Patient Health Questionnaire-9, Hamilton Depression Rating Scale and Beck Depression Inventory are general depression tools not specifically validated or recommended for routine perinatal screening in Australia, and the thresholds given are not the correct cut-offs for any instrument. The Generalised Anxiety Disorder-7 scale screens for anxiety, not depression, and is not the specified screening tool here.

• A. The PHQ-9 is not the tool specifically recommended for routine perinatal screening in Australia and the threshold given is incorrect.
• B. The Hamilton scale is a clinician-rated general depression tool, not the perinatal screening instrument recommended in Australian guidelines.
• D. The Beck Depression Inventory is a general depression measure, not the specifically validated perinatal screening tool recommended here.
• E. The GAD-7 screens for anxiety symptoms, not depression, and is not the recommended postnatal depression screening tool.

In women over 45 years with abnormal uterine bleeding, transvaginal ultrasound is the first-line investigation because it can measure endometrial thickness and identify structural causes such as fibroids, polyps or adnexal masses. If the endometrium is thickened, irregular, or the scan is inconclusive, endometrial sampling (biopsy or hysteroscopy) is then arranged to exclude hyperplasia or malignancy. This stepwise approach avoids unnecessary invasive procedures while ensuring malignancy is not missed. Risk factors here, obesity and age, raise the pretest probability of endometrial pathology, reinforcing the need for imaging before further intervention.

• B. Hysteroscopy with biopsy is reserved for cases where ultrasound shows an abnormality or bleeding persists despite normal imaging, not as the initial test.
• C. CA-125 is a tumour marker for ovarian malignancy, not a first-line test for abnormal uterine bleeding.
• D. Laparoscopy is invasive and used to assess pelvic structures when non-invasive tests have not clarified the diagnosis, not as a first-line test.
• E. FSH assesses ovarian reserve or menopausal status but does not evaluate the structural cause of bleeding.

NSAIDs such as mefenamic acid are first-line therapy for primary dysmenorrhoea because they inhibit prostaglandin synthesis, the main mechanism driving uterine contraction and pain, and are more effective than paracetamol in randomised trials. Treatment is started at or just before the onset of bleeding and continued through the painful days. The combined pill is an effective second-line option, particularly when contraception is also desired or NSAIDs are insufficient. Invasive investigation is not warranted in a typical history of primary dysmenorrhoea without red flag features for secondary causes.

• A. Laparoscopy is unnecessary in a classic presentation of primary dysmenorrhoea without features suggesting secondary causes such as endometriosis.
• C. The LNG-IUS is used for heavy menstrual bleeding and is not first-line for primary dysmenorrhoea in an adolescent who has not tried simple analgesia.
• D. Paracetamol is less effective than NSAIDs for dysmenorrhoea because it does not target prostaglandin-mediated uterine contraction.
• E. The combined pill is an effective second-line option but is not first-line when NSAIDs have not yet been tried.

This woman has low FSH, low LH, and low oestradiol, a pattern of hypogonadotropic hypogonadism, in the setting of excessive exercise and significant weight loss. This is consistent with hypothalamic amenorrhoea, in which energy deficit suppresses gonadotropin-releasing hormone pulsatility, reducing FSH and LH and subsequently oestradiol. Prolactin and TSH are both within normal range, excluding hyperprolactinaemia and thyroid dysfunction as causes. Premature ovarian insufficiency would show elevated, not low, FSH due to loss of negative feedback from failing ovaries.

• A. PCOS typically shows normal or elevated LH relative to FSH and normal or high oestradiol, not the low gonadotropins and low oestradiol seen here.
• B. Premature ovarian insufficiency is associated with elevated FSH due to ovarian failure, not the low FSH seen here.
• C. Prolactin is within the normal reference range, excluding hyperprolactinaemia as the cause.
• E. TSH is within the normal range, excluding primary hypothyroidism.

Therapeutic Guidelines recommend empirical treatment for mild to moderate pelvic inflammatory disease with a single intramuscular dose of ceftriaxone (covering Neisseria gonorrhoeae) combined with oral doxycycline (covering Chlamydia trachomatis and Mycoplasma genitalium) and oral metronidazole (covering anaerobes), given the polymicrobial nature of PID and the need to cover resistant gonococcus. Treatment should start empirically on clinical suspicion without waiting for swab results, because delayed treatment increases the risk of tubal damage and infertility. Monotherapy regimens fail to cover the full range of likely pathogens.

• A. Azithromycin alone does not adequately cover gonococcus, which may be resistant, or anaerobic organisms.
• B. Intravenous benzylpenicillin alone does not cover chlamydia, mycoplasma or resistant gonococcal strains and is reserved for severe inpatient regimens combined with other agents.
• C. Doxycycline alone does not cover Neisseria gonorrhoeae or anaerobic organisms implicated in PID.
• E. Amoxicillin-clavulanate alone does not reliably cover Neisseria gonorrhoeae or Chlamydia trachomatis.

The clinical picture of thin, fishy-smelling discharge, elevated vaginal pH above 4.5, and clue cells (epithelial cells coated with adherent bacteria) on microscopy is diagnostic of bacterial vaginosis, caused by overgrowth of anaerobic organisms including Gardnerella vaginalis with loss of normal lactobacilli. Oral metronidazole is first-line treatment per Therapeutic Guidelines, targeting anaerobic bacteria. Candidiasis instead presents with thick curd-like discharge, vulval itch and erythema, with a normal or low pH and no clue cells, and is treated with antifungal agents such as fluconazole or clotrimazole, not antibiotics.

• A. Clindamycin cream is an alternative treatment for bacterial vaginosis but is applied intravaginally, not vulvally, and oral metronidazole remains first-line.
• B. Fluconazole is an antifungal used for candidiasis, which presents with itch and thick discharge, not the picture described here.
• D. Amoxicillin does not reliably cover the anaerobic organisms responsible for bacterial vaginosis.
• E. Clotrimazole is an antifungal pessary for candidiasis, not appropriate for bacterial vaginosis.

Australian guidelines recommend opportunistic annual chlamydia screening (via first-pass urine or self-collected vaginal swab nucleic acid amplification testing) for all sexually active people aged 15-29 years, and more frequent testing is appropriate for those in remote Aboriginal and Torres Strait Islander communities given higher chlamydia prevalence and reinfection rates. If positive, treatment with azithromycin or doxycycline is given along with contact tracing and treatment of all sexual partners from the preceding 6 months to prevent reinfection and onward transmission. Chlamydia is frequently asymptomatic, so waiting for symptoms or relying on an old negative result misses most infections. Serological testing is not used for chlamydia because antibodies do not reliably indicate current infection.

• A. Serological antibody testing is not used for chlamydia diagnosis because it cannot distinguish current from past infection.
• B. Chlamydia is often asymptomatic, so waiting for symptoms would miss most infections and delay contact tracing.
• C. A negative test 18 months ago does not reflect her current risk after a new sexual partner; annual or more frequent screening is recommended.
• D. Chlamydia screening should occur opportunistically and is not tied to the cervical screening schedule, which addresses a different condition.

Migraine with aura is a UKMEC/Australian category 4 contraindication to any combined hormonal contraceptive (pill, patch or ring) because the oestrogen component further increases the risk of ischaemic stroke in women who already have an elevated baseline risk from aura. All combined hormonal methods containing oestrogen, regardless of dose or delivery route, are therefore unsuitable. Progestogen-only methods (pill, implant, injection or levonorgestrel intrauterine system) do not carry this stroke risk and are appropriate alternatives. This is a key patient safety point tested because the contraindication applies to the oestrogen component itself, not to a particular formulation.

• A. The contraceptive patch is a combined hormonal method and carries the same oestrogen-related stroke risk.
• C. The vaginal ring is a combined hormonal method and carries the same oestrogen-related stroke risk.
• D. Combined oral contraceptive pills contain oestrogen, which is contraindicated with migraine with aura.
• E. Reducing the oestrogen dose or pill-free interval does not remove the contraindication; any oestrogen-containing method is unsafe with aura.

Under the Australian National Cervical Screening Program, primary HPV testing with a negative (HPV not detected) result in an asymptomatic, average-risk woman aged 25-74 years returns her to routine 5-yearly screening. HPV testing is more sensitive than cytology for detecting the precursors of cervical cancer, which is why the screening interval was extended from 2 to 5 years when the program moved from cytology-based to HPV-based primary screening in December 2017. A 12-month or 2-year repeat would only apply to specific intermediate-risk HPV results (e.g., HPV 16/18 negative but other oncogenic types detected with no cytology abnormality, which prompts a 12-month repeat). Colposcopy is reserved for positive HPV results with abnormal reflex cytology or persistent oncogenic HPV. Cytology is now a reflex test performed only if HPV is detected, not a routine next step after a negative HPV result.

• A. A 12-month repeat applies to intermediate-risk results such as oncogenic HPV (non-16/18) detected with no cytological abnormality, not to a negative result.
• C. Colposcopy is indicated for positive HPV results with abnormal cytology or persistent infection, not for a negative screening result.
• D. The 2-year interval was the previous cytology-based program interval, superseded by the 5-year interval under HPV primary screening.
• E. Cytology is only performed as a reflex test when HPV is detected on the primary screening test, not when the result is negative.

Any postmenopausal bleeding warrants investigation for endometrial malignancy, and an endometrial thickness greater than 4-5 mm on transvaginal ultrasound in a postmenopausal woman requires histological sampling to exclude endometrial hyperplasia or carcinoma. Endometrial (pipelle) biopsy performed in the clinic is the appropriate first-line investigation because it is minimally invasive, well-tolerated and has high sensitivity for detecting endometrial cancer. Reassurance with a repeat scan delays diagnosis in a woman who already meets the threshold for sampling. Empirical progestogen treats symptoms without establishing a histological diagnosis, and hysterectomy is premature without tissue diagnosis.

• A. Progestogen trial with repeat imaging does not substitute for histological sampling in postmenopausal bleeding with a thickened endometrium.
• B. Empirical hormonal treatment does not provide a histological diagnosis and may mask underlying pathology.
• C. Hysterectomy is not performed before a tissue diagnosis has been established.
• D. The endometrial thickness already exceeds the threshold requiring tissue sampling; delaying with a repeat scan risks missing malignancy.

The combination of persistent bloating, early satiety, urinary symptoms, unintentional weight loss, a fixed irregular pelvic mass, ascites and a first-degree relative with ovarian cancer is highly suggestive of epithelial ovarian carcinoma. Malignant features on examination include irregularity, fixation to surrounding structures, bilaterality and the presence of ascites, in contrast to benign cysts which are typically mobile, smooth-walled and unilateral. A family history of ovarian cancer, particularly at a younger age, raises concern for a hereditary BRCA-related syndrome and increases pretest probability of malignancy. Functional cysts and dermoid cysts occur in younger women and do not produce this systemic symptom pattern or ascites.

• A. Endometriomas present with cyclical pelvic pain and infertility in younger women, not with ascites and a fixed irregular mass in this age group.
• B. Functional cysts occur in premenopausal women, resolve within weeks and do not cause ascites or constitutional symptoms.
• D. Dermoid cysts are usually asymptomatic, mobile and occur more commonly in younger women; they do not cause ascites or this constitutional symptom pattern.
• E. A benign cystadenoma would not typically present with a fixed irregular mass, ascites, weight loss and a strong family history.

CA-125 is a non-specific tumour marker that can be elevated by numerous benign gynaecological conditions including endometriosis, uterine fibroids, pelvic inflammatory disease, pregnancy and even menstruation, which limits its diagnostic value in premenopausal women. In postmenopausal women, CA-125 has greater specificity for malignancy and is incorporated into risk-of-malignancy index calculations alongside ultrasound features and menopausal status. A mildly elevated CA-125 in a premenopausal woman with a simple cyst and no other risk factors does not confirm cancer and should be interpreted alongside ultrasound morphology rather than in isolation. It cannot reliably distinguish tumour histological subtype and is not used as a standalone screening or monitoring test without a defined malignancy already diagnosed.

• A. CA-125 elevation alone does not confirm malignancy, particularly in premenopausal women where many benign conditions raise the marker.
• B. CA-125 level does not reliably differentiate between mucinous and serous ovarian tumour subtypes.
• C. Serial monthly testing is not the recommended approach to an incidentally found adnexal mass; management should follow ultrasound risk stratification and clinical context.
• E. Imaging appearance alone, without correlation to the marker, does not exclude malignancy, but the point here is that the marker itself is unreliable in isolation in this age group.

Stress urinary incontinence in a woman with a clear history and no red flags (haematuria, recurrent infection, voiding dysfunction) should first be managed conservatively with supervised pelvic floor muscle training for at least 3 months, as recommended by Therapeutic Guidelines and RACGP guidance. This improves urethral support and continence in a high proportion of women and avoids unnecessary invasive investigation or surgery. Weight loss and reduction of caffeine intake are also first-line adjuncts. Surgery and urodynamics are reserved for women who fail conservative treatment or have diagnostic uncertainty.

• A. Urodynamics are not required before a trial of conservative therapy in an uncomplicated case.
• B. Surgery is reserved for cases failing an adequate trial of conservative management.
• C. Anticholinergics such as oxybutynin treat urgency/overactive bladder, not pure stress incontinence.
• E. Vaginal oestrogen helps genitourinary symptoms of menopause but is not first-line for stress incontinence.